9 Results
Omalizumab Treats Multi-Food Allergy Better than Oral Immunotherapy
March 3, 2025
The high rate of allergic reactions and other intolerable side effects of oral immunotherapy in the NIH-funded trial explained the superiority of omalizumab.
Therapy Helps Peanut-Allergic Kids Tolerate Tablespoons of Peanut Butter
February 10, 2025
Eating slowly increasing amounts of peanut butter enabled 100% of kids with peanut allergy to consume 3 tablespoons of peanut butter without an allergic reaction.
Introducing Peanut in Infancy Prevents Peanut Allergy into Adolescence
May 28, 2024
Feeding children peanut products regularly from infancy to age 5 years reduced the rate of peanut allergy in adolescence by 71%, even when the children ate or avoided peanut products as desired for many years. These new findings, from a study sponsored and co-funded by the National Institutes of Health’s National Institute of Allergy and Infectious Diseases (NIAID), provide conclusive evidence that achieving long-term prevention of peanut allergy is possible through early allergen consumption.
Antibody Reduces Allergic Reactions to Multiple Foods in NIH Trial
February 25, 2024
A 16-week course of a monoclonal antibody, omalizumab, increased the amount of peanut, tree nuts, egg, milk and wheat that multi-food allergic children as young as 1 year could consume without an allergic reaction in a late-stage clinical trial.
Statement: NIH Trial Data Underpins FDA Approval of Omalizumab for Food Allergy
February 16, 2024
FDA has approved omalizumab for the reduction of allergic reactions, including anaphylaxis, that may occur with an accidental exposure to one or more foods in adults and children aged 1 year and older with food allergy. People taking omalizumab still need to avoid exposure to foods to which they are allergic.
Statement: Antibody Reduces Allergic Reactions to Multiple Foods in NIH Trial
December 19, 2023
A monoclonal antibody treatment significantly increased the amounts of multiple common foods that food-allergic children and adolescents could consume without an allergic reaction, according to a planned interim analysis of an advanced clinical trial.
Food Allergy Is Associated with Lower Risk of SARS-CoV-2 Infection
June 1, 2022
A National Institutes of Health-funded study has found that people with food allergies are less likely to become infected with SARS-CoV-2, the virus that causes COVID-19, than people without them. In addition, while previous research identified obesity as a risk factor for severe COVID-19, the new study has identified obesity and high body mass index (BMI) as associated with increased risk for SARS-CoV-2 infection. In contrast, the study determined that asthma does not increase risk for SARS-CoV-2 infection.
Oral Immunotherapy Induces Remission of Peanut Allergy in Some Young Children
January 20, 2022
A clinical trial funded by the National Institutes of Health has found that giving peanut oral immunotherapy to highly peanut-allergic children ages 1 to 3 years safely desensitized most of them to peanut and induced remission of peanut allergy in one-fifth. The immunotherapy consisted of a daily oral dose of peanut flour for 2.5 years. Remission was defined as being able to eat 5 grams of peanut protein, equivalent to 1.5 tablespoons of peanut butter, without having an allergic reaction six months after completing immunotherapy.
NIH Study of Early Predictors, Mechanisms of Food Allergy and Eczema has Begun
March 19, 2021
A study to identify prenatal and early childhood markers of high risk for food allergy and atopic dermatitis, or eczema, as well as biological pathways that lead to these conditions, has begun. The observational study of children from birth to age 3 years will examine the origins of allergic disease by integrating interdisciplinary analyses of data from more than 260 biological and environmental samples and survey responses from each of 2,500 families.
